Associated Papers
Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer.
Sito H et al.
Molecular Biology Reports, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Association of Single-Nucleotide Polymorphisms in Capecitabine Bioactivation Pathway with Adjuvant Therapy Safety in Colorectal Cancer Patients.
Cura Y et al.
Pharmaceutics, 2023
Review of genetic and pharmacogenetic differences in cytotoxic and targeted therapies for pancreatic cancer in African Americans.
Telisnor G et al.
Journal of the National Medical Association, 2023
Influence of Single-Nucleotide Polymorphisms on Clinical Outcomes of Capecitabine-Based Chemotherapy in Colorectal Cancer Patients: A Systematic Review.
Cura Y et al.
Cancers, 2023
Pharmacogenomic-guided dosing of fluoropyrimidines beyond DPYD: time for a polygenic algorithm?
Maslarinou A et al.
Frontiers in Pharmacology, 2023
Role of Genetic Polymorphisms in Drug-Metabolizing Enzyme-Mediated Toxicity and Pharmacokinetic Resistance to Anti-Cancer Agents: A Review on the Pharmacogenomics Aspect.
Narendra G et al.
Clinical Pharmacokinetics, 2022
Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives.
Pinto-Merino Á et al.
Pharmaceutics, 2022
Comprehensive analysis of important pharmacogenes in Koreans using the DMET™ platform.
Kim B et al.
Translational and Clinical Pharmacology, 2021
Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients.
Hu L et al.
Neoplasma, 2021
Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines.
Maillard M et al.
Cancer Chemotherapy and Pharmacology, 2021
Whole genome mapping and identification of single nucleotide polymorphisms of four Bangladeshi individuals and their functional significance.
Khan S et al.
Bmc Research Notes, 2021
Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing.
Aboul-Soud MAM et al.
Saudi Journal of Biological Sciences, 2021
Targeted next generation sequencing as a tool for precision medicine.
Gulilat M et al.
Bmc Medical Genomics, 2019
Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
Cohen R et al.
British Journal of Clinical Pharmacology, 2019
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation.
Cecchin E et al.
Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy, 2018
Severe acute toxicity following gemcitabine administration: A report of four cases with cytidine deaminase polymorphisms evaluation.
Hryciuk B et al.
Oncology Letters, 2018
Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity.
Hamzic S et al.
Clinical Pharmacology and Therapeutics, 2017
The chronological sequence of somatic mutations in early gastric carcinogenesis inferred from multiregion sequencing of gastric adenomas.
Lim CH et al.
Oncotarget, 2016
The influence of cytidine deaminase -33delC polymorphism on treatment outcome with high-dose cytarabine in Chinese patients with relapsed acute myeloid leukaemia.
He H et al.
Journal of Clinical Pharmacy and Therapeutics, 2015
Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.
Serdjebi C et al.
Expert Opinion on Drug Metabolism & Toxicology, 2015
Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.
Ding X et al.
Gene, 2015
Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
Yoon KA et al.
Oncology, 2015
Potentially functional SNPs (pfSNPs) as novel genomic predictors of 5-FU response in metastatic colorectal cancer patients.
Wang J et al.
Plos One, 2014
Determination of common genetic variants in cytidine deaminase (CDA) gene in Indian ethnic population.
Iyer SN et al.
Gene, 2013
Association of cytidine deaminase and xeroderma pigmentosum group D polymorphisms with response, toxicity, and survival in cisplatin/gemcitabine-treated advanced non-small cell lung cancer patients.
Ludovini V et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2011
Ethnic differences in the metabolism, toxicology and efficacy of three anticancer drugs.
Sai K et al.
Expert Opinion on Drug Metabolism & Toxicology, 2011
High-resolution melting analysis of sequence variations in the cytidine deaminase gene (CDA) in patients with cancer treated with gemcitabine.
Raynal C et al.
Therapeutic Drug Monitoring, 2010
Distribution of gemcitabine pathway genotypes in ethnic Asians and their association with outcome in non-small cell lung cancer patients.
Soo RA et al.
Lung Cancer (amsterdam, Netherlands), 2009
Pharmacogenetics in breast cancer therapy.
Tan SH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2008
Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.
Mercier C et al.
Pharmacogenetics and Genomics, 2007
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Yonemori K et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2005
Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.
Fukunaga AK et al.
The Pharmacogenomics Journal, 2004
Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients.
Wong AL et al.
Cancer Genomics & Proteomics, 0
The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.
Li H et al.
The International Journal of Biological Markers, 0